PBN0 Stock Overview

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. More details

PBN0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 20.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (A$4M)

Does not have a meaningful market cap (€55M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Alterity Therapeutics Limited Competitors

Medigene

XTRA:MDG1

€22.0m

Heidelberg Pharma

XTRA:HPHA

€120.2m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€69.6m

Price History & Performance

Summary of share price highs, lows and changes for Alterity Therapeutics
Historical stock prices
Current Share Price	AU$4.20
52 Week High	AU$4.20
52 Week Low	AU$0.64
Beta	0.48
1 Month Change	0%
3 Month Change	113.20%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	154.55%

Recent updates

Shareholder Returns

	PBN0	DE Biotechs	DE Market
7D	0%	0.2%	-3.5%
1Y	n/a	-10.2%	13.6%

Return vs Industry: Insufficient data to determine how PBN0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how PBN0 performed against the German Market.

Price Volatility

Is PBN0's price volatile compared to industry and market?
PBN0 volatility
PBN0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	11.9%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine PBN0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	10	David Stamler	alteritytherapeutics.com

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.

Alterity Therapeutics Limited Fundamentals Summary

How do Alterity Therapeutics's earnings and revenue compare to its market cap?
PBN0 fundamental statistics
Market cap	€31.78m
Earnings (TTM)	-€11.45m
Revenue (TTM)	€2.16m

14.7x

P/S Ratio

-2.8x

P/E Ratio

Is PBN0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PBN0 income statement (TTM)
Revenue	AU$3.72m
Cost of Revenue	AU$180.93k
Gross Profit	AU$3.54m
Other Expenses	AU$23.33m
Earnings	-AU$19.79m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0036
Gross Margin	95.14%
Net Profit Margin	-531.34%
Debt/Equity Ratio	0%

How did PBN0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/13 17:57
End of Day Share Price	2025/02/03 00:00
Earnings	2024/12/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alterity Therapeutics Limited is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Wasserman	Benchmark Company
George Zavoico	B. Riley Securities, Inc.
Vernon Bernardino	FBR Capital Markets & Co.